Currently out of the existing stock ratings of Reni Benjamin, 149 are a BUY (89.76%), 16 are a HOLD (9.64%), 1 are a SELL (0.6%).

Reni Benjamin

Work Performance Price Targets & Ratings Chart

Analyst Reni Benjamin, currently employed at JMP, carries an average stock price target met ratio of 44.52% that have a potential upside of 51.99% achieved within 180 days.

Reni Benjamin’s has documented 318 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SANA, Sana Biotechnology at 05-Nov-2024.

Wall Street Analyst Reni Benjamin

Analyst best performing recommendations are on CTIC (CTI BIOPHARMA CORP).
The best stock recommendation documented was for CTIC (CTI BIOPHARMA CORP) at 3/2/2022. The price target of $5 was fulfilled within 23 days with a profit of $1.63 (48.37%) receiving and performance score of 21.03.

Average potential price target upside

of $51.35 (99.22%) on BPMC (BLUEPRINT MEDICINES CORP).
of $21.85 (26.38%) on INCY (YTE).
of $17.02 (11.07%) on SGEN (SEAGEN).

BCYC Bicycle Therapeutics Ltd BPMC Blueprint Medicines Corp DCPH Deciphera Pharmaceuticals LLC EFTR Effector Therapeutics INBX Inhibrx INCY yte IOVA Iovance Biotherapeutics SGEN Seagen STRO Sutro Biopharma VYGR Voyager Therapeutics ALLO Allogene Therapeutics CGEN Compugen KURA Kura Oncology ACET Adicet Bio CTIC CTi Biopharma Corp RGNX Regenxbio ADAP Adaptimmune Therapeutics Plc ADVM Adverum Biotechnologies BCAB Bioatla CUE Cue Biopharma SPPI Spectrum Pharmaceuticals URGN UroGen Pharma Ltd AMAM Ambrx Biopharma . American Depositary Shares LVTX LAVA Therapeutics NV SANA Sana Biotechnology VSTM Verastem

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Swayampakula Ramakanth (HC WAINWRIGHT)